The latest price target for Bausch Health Companies (NYSE:BHC) was reported by RBC Capital on August 2, 2024. The analyst firm set a price target for $8.50 expecting BHC to rise to within 12 months (a possible 4.94% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Bausch Health Companies (NYSE:BHC) was provided by RBC Capital, and Bausch Health Companies maintained their sector perform rating.

The last upgrade for Bausch Health Companies Inc happened on September 20, 2023 when Jefferies raised their price target to $16. Jefferies previously had a hold for Bausch Health Companies Inc.

The last downgrade for Bausch Health Companies Inc happened on August 2, 2024 when Piper Sandler changed their price target from $9 to $3 for Bausch Health Companies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bausch Health Companies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bausch Health Companies was filed on August 2, 2024 so you should expect the next rating to be made available sometime around August 2, 2025.

While ratings are subjective and will change, the latest Bausch Health Companies (BHC) rating was a maintained with a price target of $10.00 to $8.50. The current price Bausch Health Companies (BHC) is trading at is $8.10, which is out of the analyst’s predicted range.